NASDAQ

Updated Oct 30, 9:34 AM ET

NVCR

NovoCure Limited

−$0.38 (2.86%) Today

Oct 30, 9:34 AM ET

About NVCR

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Cylvex Score

Caution

Multiple risk signals, limited coverage

Multi-factor score. Not a buy/sell signal.

Score history

Calibrating

Score history is calibrating — it appears once enough daily scores are recorded.

What goes into the score

6 axes · equal weight
AnalystWall Street consensus & target distance
GrowthEarnings growth trajectory
ProfitabilityROE, margins, cash generation
ValuationPE, PEG, price-to-book ratios
TechnicalsPrice momentum & 52-week position
RiskBeta, volatility, leverage

The Cylvex Score is a multi-factor summary for education. Not a buy/sell signal. Not investment advice.